GGrantIndex
← Leaderboards

Benjamin W. Purow

University Of Virginia

$10,419,575
Attributed
$10,627,197
Total exposure
8
Grants
7
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $902.1K · FY200825
$1M$750K$500K$250K$0
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$10,627,197 · 8

By mechanism

R01$9,773,500 · 6
R21$853,697 · 2

Top collaborators

Others in their field

Top investigators on “Malignant Neoplasms

Research focus

Malignant NeoplasmsBrain NeoplasmsResistanceIn VitroIn VivoChemotherapyRadiationReportingTumorCellsProteinsGlioblastomaMouse ModelPhenotypeTherapeutic TargetPathway InteractionsInhibitor/AntagonistStem CellsGliomaXenograft ProcedureCell SurvivalAffectTemozolomidePharmaceutical Preparations

Grant awards (30)

Vulnerabilities of MMR-deficient glioblastoma$398,997
R01 · FY2025 · NS · contact PI
Novel immunotherapeutic potential of DGKalpha inhibition for glioblastoma$359,097
R01 · FY2025 · NS · contact PI
Vulnerabilities of MMR-deficient glioblastoma$387,027
R01 · FY2024 · NS · contact PI
Novel immunotherapeutic potential of DGKalpha inhibition for glioblastoma$387,027
R01 · FY2024 · NS · contact PI
Novel immunotherapeutic potential of DGKalpha inhibition for glioblastoma$398,997
R01 · FY2023 · NS · contact PI
Vulnerabilities of MMR-deficient glioblastoma$398,997
R01 · FY2023 · NS · contact PI
Vulnerabilities of MMR-deficient glioblastoma$398,997
R01 · FY2022 · NS · contact PI
Engineering ERK-specificity for cancer suicide gene therapy$415,245
R21 · FY2020 · CA
Crosslinking conjugates to localize and activate NK cells in glioblastoma$438,452
R21 · FY2019 · NS · contact PI
Novel DGKalpha inhibitors and immunotherapy for GBM and melanoma brain metastasis$489,274
R01 · FY2018 · CA · contact PI
Novel DGKalpha inhibitors and immunotherapy for GBM and melanoma brain metastasis$58,564
R01 · FY2018 · CA · contact PI
Novel DGKalpha inhibitors and immunotherapy for GBM and melanoma brain metastasis$20,257
R01 · FY2018 · CA · contact PI
Novel DGKalpha inhibitors and immunotherapy for GBM and melanoma brain metastasis$490,853
R01 · FY2017 · CA · contact PI
Targeting diacylglycerol kinases in glioblastoma$408,495
R01 · FY2017 · CA · contact PI
Novel DGKalpha inhibitors and immunotherapy for GBM and melanoma brain metastasis$493,581
R01 · FY2016 · CA · contact PI
Targeting diacylglycerol kinases in glioblastoma$408,495
R01 · FY2016 · CA · contact PI
Novel DGKalpha inhibitors and immunotherapy for GBM and melanoma brain metastasis$493,581
R01 · FY2015 · CA · contact PI
Targeting diacylglycerol kinases in glioblastoma$408,495
R01 · FY2015 · CA · contact PI
Novel DGKalpha inhibitors and immunotherapy for GBM and melanoma brain metastasis$493,581
R01 · FY2014 · CA · contact PI
Targeting diacylglycerol kinases in glioblastoma$408,495
R01 · FY2014 · CA · contact PI
Investigation of Notch-inhibiting microRNAs in glioma$286,408
R01 · FY2013 · CA · contact PI
Investigation of Notch-inhibiting microRNAs in glioma$304,690
R01 · FY2012 · CA · contact PI
Investigating Alpha-secretase inhibitors as Notch inhibitors & anti-glioma agents$261,900
R01 · FY2012 · CA · contact PI
Investigation of Notch-inhibiting microRNAs in glioma$304,690
R01 · FY2011 · CA · contact PI
Investigating Alpha-secretase inhibitors as Notch inhibitors & anti-glioma agents$261,900
R01 · FY2011 · CA · contact PI
Investigation of Notch-inhibiting microRNAs in glioma$314,165
R01 · FY2010 · CA · contact PI
Investigating Alpha-secretase inhibitors as Notch inhibitors & anti-glioma agents$270,000
R01 · FY2010 · CA · contact PI
Investigation of Notch-inhibiting microRNAs in glioma$326,937
R01 · FY2009 · CA · contact PI
Investigating Alpha-secretase inhibitors as Notch inhibitors & anti-glioma agents$270,000
R01 · FY2009 · CA · contact PI
Investigating Alpha-secretase inhibitors as Notch inhibitors & anti-glioma agents$270,000
R01 · FY2008 · CA · contact PI